Latest news with #EmmanuelleLeyguesVP
Yahoo
16-05-2025
- Business
- Yahoo
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, May 16, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 19,129,120 Number of real voting rights* (excluding treasury shares**) 19,065,961 Theoretical number of voting rights* (including treasury shares**) 19,105,920 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 Press – Ulysse Communication Bruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@
Yahoo
16-05-2025
- Business
- Yahoo
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, May 16, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 19,129,120 Number of real voting rights* (excluding treasury shares**) 19,065,961 Theoretical number of voting rights* (including treasury shares**) 19,105,920 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 Press – Ulysse Communication Bruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@
Yahoo
07-03-2025
- Business
- Yahoo
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, March 07, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,757,159 Number of real voting rights* (excluding treasury shares**) 18,695,888 Theoretical number of voting rights* (including treasury shares**) 18,733,959 (*) Class E preference shares are non-voting(**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Press - ALIZE RP Caroline Carmagnol+33 6 64 18 99 59median@ Investors - ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 Sign in to access your portfolio
